Corrigendum to “Concurrent MEK and autophagy inhibition is required to restore cell death associated danger-signalling in Vemurafenib-resistant melanoma cells” (Biochemical Pharmacology (2015) 93(3) (290–304), (S0006295214006996), (10.1016/j.bcp.2014.12.003));Concurrent MEK and autophagy inhibition is required to restore cell death associated danger-signalling in Vemurafenib-resistant melanoma cells

Biochemical Pharmacology

Volumn 93, Issue 3, 2015, Pages 290-304

  Martin, S ^a   Dudek Peric A M ^a   Maes, H ^a   Garg, A D ^a   Gabrysiak, M ^a   Demirsoy, S ^a   Swinnen, J V ^a   Agostinis, P ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Autophagy; Cell death; Danger signalling; Melanoma; PLX4032

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; B RAF KINASE; BAFILOMYCIN A1; BORTEZOMIB; CALRETICULIN; CASPASE 3; HEAT SHOCK PROTEIN 90; INITIATION FACTOR 2ALPHA; MITOGEN ACTIVATED PROTEIN KINASE; N [3 (5 CHLORO 1H PYRROLO[2,3 B]PYRIDINE 3 CARBONYL) 2,4 DIFLUOROPHENYL]PROPANESULFONAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; VEMURAFENIB; 1,3 BUTADIENE DERIVATIVE; ENZYME INHIBITOR; INDOLE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; NITRILE; SULFONAMIDE;

A375 CELL LINE; APOPTOSIS; ARTICLE; AUTOPHAGOSOME; AUTOPHAGY; CANCER RESISTANCE; CELL DEATH; CELL FATE; CELL MATURATION; CELL PHAGOCYTOSIS; CELL POPULATION; CELL SURFACE; CELL SURVIVAL; CELL VIABILITY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DENDRITIC CELL; DRUG SENSITIVITY; DRUG TARGETING; ENDOPLASMIC RETICULUM STRESS; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNE RESPONSE; INTRACELLULAR SIGNALING; MELANOMA CELL; MOLECULAR RECOGNITION; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN CLEAVAGE; QUANTITATIVE ANALYSIS; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; COCULTURE; DRUG EFFECTS; DRUG RESISTANCE; MELANOMA; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION;

AUTOPHAGY; BUTADIENES; CELL DEATH; COCULTURE TECHNIQUES; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; HUMANS; INDOLES; MAP KINASE KINASE KINASES; MELANOMA; NITRILES; SIGNAL TRANSDUCTION; SULFONAMIDES;

EID: 84921747766     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2020.113810     Document Type: Erratum

References (70)

1. P.B. Chapman, A. Hauschild, C. Robert, J.B. Haanen, P. Ascierto, and J. Larkin Improved survival with vemurafenib in melanoma with BRAF V600E mutation N Engl J Med 364 2011 2507 2516 10.1056/NEJMoa1103782
2. H. Davies, G.R. Bignell, C. Cox, P. Stephens, S. Edkins, and S. Clegg Mutations of the BRAF gene in human cancer Nature 417 2002 949 954 10.1038/nature00766
3. C. Wellbrock, and A. Hurlstone BRAF as therapeutic target in melanoma Biochem Pharmacol 80 2010 561 567 10.1016/j.bcp.2010.03.019
4. M. Cheung, A. Sharma, S.V. Madhunapantula, and G.P. Robertson Akt3 and mutant V600E B-Raf cooperate to promote early melanoma development Cancer Res 68 2008 3429 3439 10.1158/0008-5472.CAN-07-5867
5. G.S. Inamdar, S.V. Madhunapantula, and G.P. Robertson Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail Biochem Pharmacol 80 2010 624 637 10.1016/j.bcp.2010.04.029
6. G. Bollag, P. Hirth, J. Tsai, J. Zhang, P.N. Ibrahim, and H. Cho Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma Nature 467 2010 596 599 10.1038/nature09454
7. K.T. Flaherty, U. Yasothan, and P. Kirkpatrick Vemurafenib Nat Rev Drug Discov 10 2011 811 812 10.1038/nrd3579
8. J.A. Sosman, K.B. Kim, L. Schuchter, R. Gonzalez, A.C. Pavlick, and J.S. Weber Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib N Engl J Med 366 2012 707 714 10.1056/NEJMoa1112302
9. K.T. Flaherty, I. Puzanov, K.B. Kim, A. Ribas, G.A. McArthur, and J.A. Sosman Inhibition of mutated, activated BRAF in metastatic melanoma N Engl J Med 363 2010 809 819 10.1056/NEJMoa1002011
10. J. Villanueva, A. Vultur, J.T. Lee, R. Somasundaram, M. Fukunaga-Kalabis, and A.K. Cipolla Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K Cancer Cell 18 2010 683 695 10.1016/j.ccr.2010.11.023
11. Y. Shao, and A.E. Aplin BH3-only protein silencing contributes to acquired resistance to PLX4720 in human melanoma Cell Death Differ 19 2012 2029 2039 10.1038/cdd.2012.94
12. R.B. Corcoran, H. Ebi, A.B. Turke, E.M. Coffee, M. Nishino, and A.P. Cogdill EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib Cancer Discov 2 2012 227 235 10.1158/2159-8290.CD-11-0341
13. A. Prahallad, C. Sun, S. Huang, F. Di Nicolantonio, R. Salazar, and D. Zecchin Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR Nature 483 2012 100 103 10.1038/nature10868
14. R. Nazarian, H. Shi, Q. Wang, X. Kong, R.C. Koya, and H. Lee Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation Nature 468 2010 973 977 10.1038/nature09626
15. N. Wagle, C. Emery, M.F. Berger, M.J. Davis, A. Sawyer, and P. Pochanard Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling J Clin Oncol 29 2011 3085 3096 10.1200/JCO.2010.33.2312
16. H. Escuin-Ordinas, M. Atefi, Y. Fu, A. Cass, C. Ng, and R.R. Huang COX-2 inhibition prevents the appearance of cutaneous squamous cell carcinomas accelerated by BRAF inhibitors Mol Oncol 8 2014 250 260 10.1016/j.molonc.2013.11.005
17. K.T. Flaherty, C. Robert, P. Hersey, P. Nathan, C. Garbe, and M. Milhem Improved survival with MEK inhibition in BRAF-mutated melanoma N Engl J Med 367 2012 107 114 10.1056/NEJMoa1203421
18. K.T. Flaherty, J.R. Infante, A. Daud, R. Gonzalez, R.F. Kefford, and J. Sosman Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations N Engl J Med 367 2012 1694 1703 10.1056/NEJMoa1210093
19. X.H. Ma, S.F. Piao, S. Dey, Q. McAfee, G. Karakousis, and J. Villanueva Targeting ER stress-induced autophagy overcomes BRAF inhibitor resistance in melanoma J Clin Invest 124 2014 1406 1417 10.1172/jci70454
20. J.H. Ahn, and M. Lee Autophagy-dependent survival of mutant B-Raf melanoma cells selected for resistance to apoptosis induced by inhibitors against oncogenic B-Raf Biomol Ther (Seoul) 21 2013 114 120 10.4062/biomolther.2013.012
21. D.J. Klionsky, F.C. Abdalla, H. Abeliovich, R.T. Abraham, A. Acevedo-Arozena, and K. Adeli Guidelines for the use and interpretation of assays for monitoring autophagy Autophagy 8 2012 445 544
22. H. Maes, S. Martin, T. Verfaillie, and P. Agostinis Dynamic interplay between autophagic flux and Akt during melanoma progression in vitro Exp Dermatol 23 2014 101 106 10.1111/exd.12298
23. R.K. Amaravadi, and C.B. Thompson The roles of therapy-induced autophagy and necrosis in cancer treatment Clin Cancer Res 13 2007 7271 7279 10.1158/1078-0432.CCR-07-1595
24. D. Beck, H. Niessner, K.S. Smalley, K. Flaherty, K.H. Paraiso, and C. Busch Vemurafenib potently induces endoplasmic reticulum stress-mediated apoptosis in BRAFV600E melanoma cells Sci Signal 6 2013 ra7 10.1126/scisignal.2003057
25. A.D. Garg, D.V. Krysko, T. Verfaillie, A. Kaczmarek, G.B. Ferreira, and T. Marysael A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death EMBO J 31 2012 1062 1079 10.1038/emboj.2011.497
26. T. Panaretakis, O. Kepp, U. Brockmeier, A. Tesniere, A.C. Bjorklund, and D.C. Chapman Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death EMBO J 28 2009 578 590 10.1038/emboj.2009.1
27. I. Martins, O. Kepp, F. Schlemmer, S. Adjemian, M. Tailler, and S. Shen Restoration of the immunogenicity of cisplatin-induced cancer cell death by endoplasmic reticulum stress Oncogene 30 2011 1147 1158 10.1038/onc.2010.500
28. A.D. Garg, A.M. Dudek, G.B. Ferreira, T. Verfaillie, P. Vandenabeele, and D.V. Krysko ROS-induced autophagy in cancer cells assists in evasion from determinants of immunogenic cell death Autophagy 2013 9
29. I. Martins, Y. Wang, M. Michaud, Y. Ma, A.Q. Sukkurwala, and S. Shen Molecular mechanisms of ATP secretion during immunogenic cell death Cell Death Differ 2013 10.1038/cdd.2013.75
30. A.M. Dudek, A.D. Garg, D.V. Krysko, D. De Ruysscher, and P. Agostinis Inducers of immunogenic cancer cell death Cytokine Growth Factor Rev 24 2013 319 333 10.1016/j.cytogfr.2013.01.005
31. R. Spisek, A. Charalambous, A. Mazumder, D.H. Vesole, S. Jagannath, and M.V. Dhodapkar Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications Blood 109 2007 4839 4845 10.1182/blood-2006-10-054221
32. A.D. Garg, S. Martin, J. Golab, and P. Agostinis Danger signalling during cancer cell death: origins, plasticity and regulation Cell Death Differ 2014 10.1038/cdd.2013.48
33. D.V. Krysko, A.D. Garg, A. Kaczmarek, O. Krysko, P. Agostinis, and P. Vandenabeele Immunogenic cell death and DAMPs in cancer therapy Nat Rev Cancer 12 2012 860 875 10.1038/nrc3380
34. A.D. Garg, A.M. Dudek, and P. Agostinis Cancer immunogenicity, danger signals, and DAMPs: what, when, and how? Biofactors 39 2013 355 367 10.1002/biof.1125
35. A.M. Dudek, S. Martin, A.D. Garg, and P. Agostinis Immature, semi-mature, and fully mature dendritic cells: toward a DC-cancer cells interface that augments anticancer immunity Front Immunol 4 2013 438 10.3389/fimmu.2013.00438
36. G. Kroemer, L. Galluzzi, O. Kepp, and L. Zitvogel Immunogenic cell death in cancer therapy Annu Rev Immunol 31 2013 51 72 10.1146/annurev-immunol-032712-100008
37. D. Iliopoulos, C. Ernst, Z. Steplewski, J.A. Jambrosic, U. Rodeck, and M. Herlyn Inhibition of metastases of a human melanoma xenograft by monoclonal antibody to the GD2/GD3 gangliosides J Natl Cancer Inst 81 1989 440 444
38. D. Herlyn, D. Iliopoulos, P.J. Jensen, A. Parmiter, J. Baird, and H. Hotta In vitro properties of human melanoma cells metastatic in nude mice Cancer Res 50 1990 2296 2302
39. G.B. Ferreira, E. van Etten, K. Lage, D.A. Hansen, Y. Moreau, and C.T. Workman Proteome analysis demonstrates profound alterations in human dendritic cell nature by TX527, an analogue of vitamin D Proteomics 9 2009 3752 3764 10.1002/pmic.200800848
40. E. Sala, L. Mologni, S. Truffa, C. Gaetano, G.E. Bollag, and C. Gambacorti-Passerini BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells Mol Cancer Res 6 2008 751 759 10.1158/1541-7786.MCR-07-2001
41. H. Maes, A. Kuchnio, A. Peric, S. Moens, K. Nys, and K. De Bock Tumor vessel normalization by chloroquine independent of autophagy Cancer Cell 26 2014 190 206 10.1016/j.ccr.2014.06.025
42. G.A. McArthur, P.B. Chapman, C. Robert, J. Larkin, J.B. Haanen, and R. Dummer Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study Lancet Oncol 15 2014 323 332 10.1016/s1470-2045(14)70012-9
43. T.R. Wagenaar, L. Ma, B. Roscoe, S.M. Park, D.N. Bolon, and M.R. Green Resistance to vemurafenib resulting from a novel mutation in the BRAFV600E kinase domain Pigment Cell Melanoma Res 27 2014 124 133 10.1111/pcmr.12171
44. J. Tsai, J.T. Lee, W. Wang, J. Zhang, H. Cho, and S. Mamo Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity Proc Natl Acad Sci U S A 105 2008 3041 3046 10.1073/pnas.0711741105
45. A.D. Garg, A.M. Dudek, and P. Agostinis Calreticulin surface exposure is abrogated in cells lacking, chaperone-mediated autophagy-essential gene, LAMP2A Cell Death Dis 4 2013 e826 10.1038/cddis.2013.372
46. A.D. Garg, D.V. Krysko, P. Vandenabeele, and P. Agostinis Hypericin-based photodynamic therapy induces surface exposure of damage-associated molecular patterns like HSP70 and calreticulin Cancer Immunol Immunother 61 2012 215 221 10.1007/s00262-011-1184-2
47. Y. Krelin, L. Berkovich, M. Amit, and Z. Gil Association between tumorigenic potential and the fate of cancer cells in a syngeneic melanoma model PLOS ONE 8 2013 e62124 10.1371/journal.pone.0062124
48. H.M. Ni, A. Bockus, A.L. Wozniak, K. Jones, S. Weinman, and X.M. Yin Dissecting the dynamic turnover of GFP-LC3 in the autolysosome Autophagy 7 2011 188 204
49. M.L. Marino, P. Pellegrini, G. Di Lernia, M. Djavaheri-Mergny, S. Brnjic, and X. Zhang Autophagy is a protective mechanism for human melanoma cells under acidic stress J Biol Chem 287 2012 30664 30676 10.1074/jbc.M112.339127
50. L.M. Davids, B. Kleemann, S. Cooper, and S.H. Kidson Melanomas display increased cytoprotection to hypericin-mediated cytotoxicity through the induction of autophagy Cell Biol Int 33 2009 1065 1072 10.1016/j.cellbi.2009.06.026
51. J.L. Armstrong, M. Corazzari, S. Martin, V. Pagliarini, L. Falasca, and D.S. Hill Oncogenic B-RAF signaling in melanoma impairs the therapeutic advantage of autophagy inhibition Clin Cancer Res 17 2011 2216 2226 10.1158/1078-0432.CCR-10-3003
52. M.M. Chan, L.E. Haydu, A.M. Menzies, M.W. Azer, O. Klein, and M. Lyle The nature and management of metastatic melanoma after progression on BRAF inhibitors: effects of extended BRAF inhibition Cancer 2014 10.1002/cncr.28851
53. E. Romano, S. Pradervand, A. Paillusson, J. Weber, K. Harshman, and K. Muehlethaler Identification of multiple mechanisms of resistance to vemurafenib in a patient with BRAFV600E-mutated cutaneous melanoma successfully rechallenged after progression Clin Cancer Res 19 2013 5749 5757 10.1158/1078-0432.ccr-13-0661
54. L. Menger, E. Vacchelli, S. Adjemian, I. Martins, Y. Ma, and S. Shen Cardiac glycosides exert anticancer effects by inducing immunogenic cell death Sci Transl Med 4 2012 143ra199 10.1126/scitranslmed.3003807
55. L. Zitvogel, and G. Kroemer Anticancer immunochemotherapy using adjuvants with direct cytotoxic effects J Clin Invest 119 2009 2127 2130 10.1172/JCI39991
56. R.Q. Peng, Y.B. Chen, Y. Ding, R. Zhang, X. Zhang, and X.J. Yu Expression of calreticulin is associated with infiltration of T-cells in stage IIIB colon cancer World J Gastroenterol 16 2010 2428 2434
57. R. Zappasodi, S.M. Pupa, G.C. Ghedini, I. Bongarzone, M. Magni, and A.D. Cabras Improved clinical outcome in indolent B-cell lymphoma patients vaccinated with autologous tumor cells experiencing immunogenic death Cancer Res 70 2010 9062 9072 10.1158/0008-5472.CAN-10-1825
58. P.A. Ott, T. Henry, S.J. Baranda, D. Frleta, O. Manches, and D. Bogunovic Inhibition of both BRAF and MEK in BRAF(V600E) mutant melanoma restores compromised dendritic cell (DC) function while having differential direct effects on DC properties Cancer Immunol Immunother 62 2013 811 822 10.1007/s00262-012-1389-z
59. J.S. Wilmott, G.V. Long, J.R. Howle, L.E. Haydu, R.N. Sharma, and J.F. Thompson Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma Clin Cancer Res 18 2012 1386 1394 10.1158/1078-0432.CCR-11-2479
60. D.A. Knight, S.F. Ngiow, M. Li, T. Parmenter, S. Mok, and A. Cass Host immunity contributes to the anti-melanoma activity of BRAF inhibitors J Clin Invest 123 2013 1371 1381 10.1172/JCI66236
61. J. Mestas, and C.C. Hughes Of mice and not men: differences between mouse and human immunology J Immunol 172 2004 2731 2738
62. S. Sridharan, K. Jain, and A. Basu Regulation of autophagy by kinases Cancers (Basel) 3 2011 2630 2654 10.3390/cancers3022630
63. U. Sivaprasad, and A. Basu Inhibition of ERK attenuates autophagy and potentiates tumour necrosis factor-alpha-induced cell death in MCF-7 cells J Cell Mol Med 12 2008 1265 1271 10.1111/j.1582-4934.2008.00282.x
64. P. Martin, M.C. Poggi, J.C. Chambard, K.E. Boulukos, and P. Pognonec Low dose cadmium poisoning results in sustained ERK phosphorylation and caspase activation Biochem Biophys Res Commun 350 2006 803 807 10.1016/j.bbrc.2006.09.126
65. M.L. Goodall, T. Wang, K.R. Martin, M.G. Kortus, A.L. Kauffman, and J.M. Trent Development of potent autophagy inhibitors that sensitize oncogenic BRAF V600E mutant melanoma tumor cells to vemurafenib Autophagy 10 2014 1120 1136 10.4161/auto.28594
66. M. Michaud, I. Martins, A.Q. Sukkurwala, S. Adjemian, Y. Ma, and P. Pellegatti Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice Science 334 2011 1573 1577 10.1126/science.1208347
67. A.D. Garg, A.M. Dudek, and P. Agostinis Autophagy-dependent suppression of cancer immunogenicity and effector mechanisms of innate and adaptive immunity OncoImmunology 2 2013 e26260 10.4161/onci.19750
68. R.A. Ellis, S. Horswell, T. Ness, J. Lumsdon, S.A. Tooze, and N. Kirkham Prognostic impact of p62 expression in cutaneous malignant melanoma J Invest Dermatol 134 2014 1476 1478 10.1038/jid.2013.497
69. A. Tarhini Immune-mediated adverse events associated with ipilimumab ctla-4 blockade therapy: the underlying mechanisms and clinical management Scientifica (Cairo) 2013 2013 857519 10.1155/2013/857519
70. J.R. Thumar, and H.M. Kluger Ipilimumab: a promising immunotherapy for melanoma Oncology (Williston Park) 24 2010 1280 1288